Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polatuzumab + Bendamustine + Rituximab in Relapsed/Refractory Mantle Cell Lymphoma
2024-518704-41-00Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of polatuzumab vedotin, bendamustine and rituximab in mantle cell lymphoma (MCL), sponsored by Medical University of Vienna. Primary endpoint: Safety, response assessment and duration. Started Jul 2023; status: completed.
02
Drugs
polatuzumab vedotinbendamustinerituximab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2024-518704-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518704-41-00.